Piper Sandler Remains a Hold on Becton Dickinson (BDX)

In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Becton Dickinson, with a price target of $159.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Bednar is an analyst with an average return of -5.4% and a 38.90% success rate. Bednar covers the Healthcare sector, focusing on stocks such as NovoCure, Merit Medical Systems, and Align Tech.

In addition to Piper Sandler, Becton Dickinson also received a Hold from RBC Capital’s Shagun Singh Chadha in a report issued on April 14. However, on April 9, Barclays maintained a Buy rating on Becton Dickinson (NYSE: BDX).

Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.25 billion and a net profit of $382 million. In comparison, last year the company earned a revenue of $5.17 billion and had a net profit of $303 million

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year.